John Matthew Koomen

John Matthew Koomen

Auto-generated profile, based on publicly available information

John Matthew Koomen

Molecular Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
BCBenjamin C. Creelan
Benjamin C. Creelan
CWChao Wang
Chao Wang
JTJamie K. Teer
Jamie K. Teer
ETEric M. Toloza
Eric M. Toloza
JYJiqiang Yao
Jiqiang Yao
SAScott J. Antonia
Scott J. Antonia

28 February 2010 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
JLJiannong Li
Jiannong Li
URUwe Rix
Uwe Rix
BFBin Fang
Bin Fang
YBYun Bai
Yun Bai
AEArthur Edwards
Arthur Edwards
EHEric Haura
Eric Haura
Determining relevant targets of promiscuous kinase inhibitors has proven difficult. A combination of two mass spectrometry–based proteomic approaches, RNAi depletion and rescue studies with drug-resistant mutants now reveal that SRC, FYN and EGFR are functionally important targets of dasatinib in lung cancer cells. We describe a strategy for comprehending signaling pathways that are active in lung cancer cells and that are targeted by dasatinib using chemical proteomics to identify direct interacting proteins combined with immunoaffinity purification of tyrosine-phosphorylated peptides corresponding to activated tyrosine kinases. We identified nearly 40 different kinase targets of dasatinib. These include SRC-family kinase (SFK) members (LYN, SRC, FYN, LCK and YES), nonreceptor tyrosine kinases (FRK, BRK and ACK) and receptor tyrosine kinases (Ephrin receptors, DDR1 and EGFR). Using quantitative phosphoproteomics, we identified peptides corresponding to autophosphorylation sites of these tyrosine kinases that are inhibited in a concentration-dependent manner by dasatinib. Using drug-resistant gatekeeper mutants, we show that SFKs (particularly SRC and FYN), as well as EGFR, are relevant targets for dasatinib action. The combined mass spectrometry–based approach described here provides a system-level view of dasatinib action in cancer cells and suggests both functional targets and a rationale for combinatorial therapeutic strategies.

31 March 2022 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
PAPatrick B. Ampomah
Patrick B. Ampomah
BCBishuang Cai
Bishuang Cai
SSSantosh R. Sukka
Santosh R. Sukka
BGBrennan D. Gerlach
Brennan D. Gerlach
AYArif Yurdagul
Arif Yurdagul
ITIra Tabas
Ira Tabas

12 February 2019 in Science Signaling
Verified
Journal Article
Closed access
PDF file
MRMaria C. Ramello
Maria C. Ramello
IBIsmahène Benzaïd
Ismahène Benzaïd
BKBrent M. Kuenzi
Brent M. Kuenzi
MLMaritza Lienlaf-Moreno
Maritza Lienlaf-Moreno
WKWendy M. Kandell
Wendy M. Kandell
DADaniel Abate-Daga
Daniel Abate-Daga
The total length of CAR intracellular domains determines interactions with endogenous proteins to promote TCR signaling.

8 August 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
PSPaul Stewart
Paul Stewart
EWEric A. Welsh
Eric A. Welsh
RSRobbert J. C. Slebos
Robbert J. C. Slebos
BFBin Fang
Bin Fang
VIVictoria Izumi
Victoria Izumi
EHEric Haura
Eric Haura
How genomic and transcriptomic alterations affect the functional proteome in lung cancer is not fully understood. Here, we integrate DNA copy number, somatic mutations, RNA-sequencing, and expression proteomics in a cohort of 108 squamous cell lung cancer (SCC) patients. We identify three proteomic subtypes, two of which (Inflamed, Redox) comprise 87% of tumors. The Inflamed subtype is enriched with neutrophils, B-cells, and monocytes and expresses more PD-1. Redox tumours are enriched for oxidation-reduction and glutathione pathways and harbor more NFE2L2/KEAP1 alterations and copy gain in the 3q2 locus. Proteomic subtypes are not associated with patient survival. However, B-cell-rich tertiary lymph node structures, more common in Inflamed, are associated with better survival. We identify metabolic vulnerabilities (TP63, PSAT1, and TFRC) in Redox. Our work provides a powerful resource for lung SCC biology and suggests therapeutic opportunities based on redox metabolism and immune cell infiltrates.

1 April 2010 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
CTC. Eric Thomas
C. Eric Thomas
WSWade Sexton
Wade Sexton
KBKaaron Benson
Kaaron Benson
RSRebecca Sutphen
Rebecca Sutphen
JKJohn Koomen
John Koomen
Background: Urine is a useful source of protein for biomarker discovery and assessment because it is readily available, can be obtained by noninvasive collection methods, and enables monitoring of a wide range of physiologic processes and diseases. Urine aliquots provide enough protein for multiple analyses, combining current protocols with new techniques. Conclusions: Standardized collection and processing protocols are now being established and new methods for protein detection and quantification are emerging to complement traditional immunoassays. The current state of urine collection, specimen processing, and storage is reviewed with regard to discovery and quantification of protein biomarkers for cancer. Cancer Epidemiol Biomarkers Prev; 19(4); 953–9. ©2010 AACR.